[artículo]
Título : |
A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence |
Tipo de documento: |
texto impreso |
Autores: |
Raymond F. Anton, Autor ; Henry R. Kranzler, Autor ; Christopher Breder, Autor |
Fecha de publicación: |
2023 |
Artículo en la página: |
pp. 5-12 |
Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
Palabras clave: |
Alcoholismo, Antipsicóticos, Piperazinas, Quinolonas. |
Resumen: |
The purpose of this study was to compare the efficacy and safety of aripiprazole with placebo in the treatment of alcoholics. In this 12-week multicenter, double-blind study, 295 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition alcohol dependence were randomized to treatment with aripiprazole (initiated at 2 mg/d, titrated to a maximum dose of 30mg/d at day 28) or placebo after screening, wherein patients maintained alcohol abstinence for 3 days or more. |
Link: |
./index.php?lvl=notice_display&id=30866 |
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 1 (Febrero) . - pp. 5-12
[artículo] A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence [texto impreso] / Raymond F. Anton, Autor ; Henry R. Kranzler, Autor ; Christopher Breder, Autor . - 2023 . - pp. 5-12. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 1 (Febrero) . - pp. 5-12
Palabras clave: |
Alcoholismo, Antipsicóticos, Piperazinas, Quinolonas. |
Resumen: |
The purpose of this study was to compare the efficacy and safety of aripiprazole with placebo in the treatment of alcoholics. In this 12-week multicenter, double-blind study, 295 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition alcohol dependence were randomized to treatment with aripiprazole (initiated at 2 mg/d, titrated to a maximum dose of 30mg/d at day 28) or placebo after screening, wherein patients maintained alcohol abstinence for 3 days or more. |
Link: |
./index.php?lvl=notice_display&id=30866 |
|